Finer Wealth Management’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$633K Buy
2,419
+9
+0.4% +$2.31K 0.25% 57
2026
Q2
$607K Buy
2,410
+92
+4% +$19.8K 0.27% 54
2026
Q1
$504K Buy
2,318
+9
+0.4% +$2K 0.25% 57
2025
Q4
$528K Buy
2,309
+1,287
+126% +$293K 0.26% 55
2025
Q3
$237K Buy
+1,022
New +$208K 0.12% 79
2025
Q2
– Sell
-1,022
Closed -$214K – 87
2025
Q1
$214K Buy
+1,022
New +$199K 0.13% 79
2024
Q4
– Sell
-1,025
Closed -$202K – 83
2024
Q3
$202K Buy
+1,025
New +$191K 0.12% 75

Other funds holding ABBV

Finer Wealth Management's ABBV Position: Q3 2026 in Review

Finer Wealth Management increased its AbbVie (ABBV) stake by 0.37% in Q3 2026, buying an estimated $2.31K and bringing the position to 2,419 shares worth $633K. The position accounts for 0.25% of the portfolio, ranked #57.

Finer Wealth Management first reported a position in ABBV in Q3 2024 and has held it in 7 quarters since. 2,777 funds tracked by Wall St. Rank hold ABBV as of Q3 2026.

  • Finer Wealth Management held 2,419 shares of AbbVie worth $633K as of Q3 2026.
  • Finer Wealth Management bought 9 AbbVie shares in Q3 2026, an estimated $2.31K.
  • AbbVie made up 0.25% of Finer Wealth Management's portfolio in Q3 2026, its #57 holding.
  • Finer Wealth Management first reported a position in AbbVie in Q3 2024 and has held it in 7 quarters since.
  • 2,777 funds tracked by Wall St. Rank held AbbVie as of Q3 2026.

Based on Finer Wealth Management's 13F filing for Q3 2026, filed 16 Oct 2026.